HUE025349T2 - Hidroxamsav származékok - Google Patents

Hidroxamsav származékok Download PDF

Info

Publication number
HUE025349T2
HUE025349T2 HUE10733747A HUE10733747A HUE025349T2 HU E025349 T2 HUE025349 T2 HU E025349T2 HU E10733747 A HUE10733747 A HU E10733747A HU E10733747 A HUE10733747 A HU E10733747A HU E025349 T2 HUE025349 T2 HU E025349T2
Authority
HU
Hungary
Prior art keywords
ion ion
cancer
compounds
disease
compound
Prior art date
Application number
HUE10733747A
Other languages
English (en)
Inventor
Yu Chen
Yi Chen
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of HUE025349T2 publication Critical patent/HUE025349T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0013—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group without a metal-carbon linkage
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/10—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F15/00—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table
    • C07F15/0006—Compounds containing elements of Groups 8, 9, 10 or 18 of the Periodic Table compounds of the platinum group
    • C07F15/0086—Platinum compounds
    • C07F15/0093—Platinum compounds without a metal-carbon linkage
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Pyridine Compounds (AREA)
  • Saccharide Compounds (AREA)

Claims (5)

  1. Szabadalmi ígé«yprii:ttoR h saerisri vsgyöfei vagy smaïc gÿâfppyésxetiieg elibgäfci» s^s:
    képlet. I alaol ZnmcsjetetU JK 5. 4,7, vagy 8; 5 F
    és Xi és X2, :mtedegyike: fijggeüeaätfealogeo vagy DS02RCî amelyben. R* alk% alksni?, vagy aMcmiL
  2. 2. Âz 1.. igénypont szerion vegyülő« vagy sós ahol a vegyüfet 10
    vagy
  3. 3. A 2. igénypont szerintivegyüld vagy só, amely 15
  4. 4. M 1-3, Igénypontok bármelyike szerinti vegyniet ahol a só a kiend, bromid, jodid* szuífái, lásauiiat Éad&màk nitrát feszit, eiMt nrfntisiipnÉs iri&atacetáí, ^stStatak ginlam>tjáts giniarat pialát, maisat szufceiaát, tejárát, íartarát, toszilit s&dielÄ íaktát, ssatïalinsanifeîât, vagy aceÄ 5, teriafem: 1-4 J:géK^omofcM«aepkö szerinti vegyelétet és egy gyógyszerészetileg el fogadható hordozóanyagot. #, Az M. igénypontok bsmselyike szerkői Vegyidet vagy só vágy m 3.. Igénypont saserfeő kompozíció felhasználásra neopiasóikus betegség vagy iromimbetegség kezelésére.
  5. 5 f, A 6. igénypoat szerinii vegySlef, sé vagy kjnptzfcib, ábol îï geoplasxtikas betegség Ící. vsa választva a következők közöli: tidörák. fej és nyak rák, központi idegrendszer rák, prosztatarák, bereráln eekaectalis rák, itanyáimingy rák, xnájrak, gyomőrrák, epeiráktas rák, nyelőcső rák, gasttokrtesbnalfe stroma tumor, mellrák, méknyakrák, peteiészek rákí: tnélrrák, fonMnria, lymphomák.; myeloma multiplex,, melanoma, Nsalis sejt ememems,, sgyamöas sejt cateimirna, Mlyagrák, veseták, szarkőtna, mesothelioma, 1Θ íísymoma, myelodyspiastiknS szm#dina és myeloproltlerativ betegség.
HUE10733747A 2009-01-23 2010-01-07 Hidroxamsav származékok HUE025349T2 (hu)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14700209P 2009-01-23 2009-01-23
US15649609P 2009-02-28 2009-02-28
US25215609P 2009-10-15 2009-10-15
US25265209P 2009-10-17 2009-10-17

Publications (1)

Publication Number Publication Date
HUE025349T2 true HUE025349T2 (hu) 2016-02-29

Family

ID=42356377

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE10733747A HUE025349T2 (hu) 2009-01-23 2010-01-07 Hidroxamsav származékok

Country Status (17)

Country Link
US (3) US8609864B2 (hu)
EP (1) EP2389375B1 (hu)
JP (1) JP5576402B2 (hu)
CN (1) CN102186842B (hu)
CA (1) CA2750413C (hu)
CY (1) CY1116602T1 (hu)
DK (1) DK2389375T3 (hu)
ES (1) ES2544803T3 (hu)
HR (1) HRP20150778T1 (hu)
HU (1) HUE025349T2 (hu)
ME (1) ME02254B (hu)
PL (1) PL2389375T3 (hu)
PT (1) PT2389375E (hu)
RS (1) RS54192B1 (hu)
SI (1) SI2389375T1 (hu)
SM (1) SMT201500196B (hu)
WO (1) WO2010085377A2 (hu)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9174970B2 (en) 2008-01-22 2015-11-03 Dow Agrosciences Llc 5-fluoro pyrimidine derivatives
CA2750413C (en) * 2009-01-23 2016-06-21 Northlake Biosciences Llc Hydroxamic acid derivatives
UA106889C2 (uk) 2009-08-07 2014-10-27 ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі Похідні n1-ацил-5-фторпіримідинону
CA2769073C (en) 2009-08-07 2018-07-24 Dow Agrosciences Llc N1-sulfonyl-5-fluoropyrimidinone derivatives
UA112284C2 (uk) 2009-08-07 2016-08-25 ДАУ АГРОСАЙЄНСІЗ ЕлЕлСі Похідні 5-фторпіримідинону
UA107671C2 (en) * 2009-08-07 2015-02-10 Dow Agrosciences Llc N1-substityted-5-fluoro-2-oxopyrimidinone-1(2h)-carboxamide derivatives
CN102791135B (zh) 2010-01-07 2015-05-20 陶氏益农公司 噻唑并[5,4-d]嘧啶以及它们作为农用化学品的用途
CN101928234B (zh) * 2010-01-15 2012-12-12 北京欧凯纳斯科技有限公司 6/7-（杂）芳基-n-羟基己/庚酰胺化合物及其制备方法
WO2011113175A1 (zh) * 2010-03-15 2011-09-22 Gao Feng 阿糖胞苷前药衍生物及其在抗癌抗肿瘤中的用途
US8980909B2 (en) * 2011-01-12 2015-03-17 Crystal Biopharmaceutical Llc HDAC inhibiting derivatives of camptothecin
JP6128658B2 (ja) 2011-08-17 2017-05-17 アダマ・マクテシム・リミテッド ５−フルオロ−４−イミノ−３−（置換）−３，４−ジヒドロピリミジン−２−（１ｈ）−オン誘導体
CN102993102B (zh) * 2011-09-16 2016-08-24 杭州民生药业有限公司 [1-甲基-2-(7’-庚异羟肟酸基)-5-n，n-二(2’-氯乙基)]-1h-苯并咪唑的合成方法
ME03088B (me) * 2011-09-18 2019-01-20 Euro Celtique Sa Postupak za proizvodnju stabilnog, injektabilnog rastvora noradrenalina niske koncentracije
CN102432654A (zh) * 2011-09-26 2012-05-02 宋云龙 吉西他滨酰胺衍生物及其制备方法和用途
AR092790A1 (es) 2012-02-01 2015-05-06 Euro Celtique Sa Derivados bencimidazolicos del acido hidroxamico
CN102584737A (zh) * 2012-02-07 2012-07-18 盛世泰科生物医药技术(苏州)有限公司 抑制组蛋白去乙酰酶的物质的组成和使用
EP2725029A1 (en) * 2012-10-29 2014-04-30 Laboratoire Biodim New antibacterial compounds and biological applications thereof
CN104994859B (zh) 2012-12-28 2018-10-26 阿达玛马克西姆股份有限公司 1-(取代的苯甲酰基)-5-氟-4-亚氨基-3-甲基-3,4-二氢嘧啶-2(1h)-酮衍生物
MX2015008441A (es) 2012-12-28 2015-09-23 Dow Agrosciences Llc Derivados de n-(sustituido)-5-fluoro-4-imino-3-metil-2-oxo-3, 4-dihidropirimidin-1 (2h)-carboxilato.
RU2015131149A (ru) 2012-12-28 2017-02-03 ДАУ АГРОСАЙЕНСИЗ ЭлЭлСи N-(замещенные)-5-фтор-4-имино-3-метил-2-оксо-3,4-дигидропиримидин-1(2н)-карбоксамидные производные
MX2015008565A (es) 2012-12-31 2015-09-07 Dow Agrosciences Llc Derivados de 3-alquil-5-fluoro-4-sustituido-imino-3,4-dihidropirim idin-2(1h)-ona como fungicidas.
CN103340845B (zh) * 2013-06-26 2015-03-18 浙江省食品药品检验研究院 药物组合物
JP6212831B2 (ja) * 2013-12-04 2017-10-18 杭州源昶医薬科技有限公司 ゲムシタビン誘導体、該誘導体を含む組成物及び該誘導体の製薬用途
UA124962C2 (uk) 2013-12-31 2021-12-22 Адама Махтешім Лтд. Синергічні фунгіцидні суміші та композиції для контролю грибків
WO2015103142A1 (en) 2013-12-31 2015-07-09 Dow Agrosciences Llc 5-fluoro-4-imino-3-(alkyl/substituted alkyl)-1- (arylsulfonyl)-3,4-dihydropyrimidin-2(1h)-one and processes for their preparation
WO2015117116A1 (en) 2014-02-03 2015-08-06 Halliburton Energy Services, Inc. Optimizing a grid for finite element solutions for subterranean region simulations
GB201409471D0 (en) * 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409488D0 (en) 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
GB201409485D0 (en) * 2014-05-28 2014-07-09 Euro Celtique Sa Pharmaceutical composition
MX2017005158A (es) * 2014-10-28 2017-07-27 Shionogi & Co Derivado heterociclico que tiene actividad de activacion de proteina cinasa activada por adenosina monofostato (ampk).
PT3297992T (pt) 2015-05-22 2020-03-17 Chong Kun Dang Pharmaceutical Corp Compostos derivados de alquilo heterocíclicos como inibidores seletivos da histona desacetilase e composições farmacêuticas que compreendem os mesmos
EP3347099B1 (en) * 2015-09-10 2023-10-25 Becton, Dickinson and Company Cyclophosphamide analogs for use as immunogens and assay conjugates for an immunoassay of cyclophosphamide and ifosfamide
AU2016426574B2 (en) * 2016-10-11 2023-07-13 Euro-Celtique S.A. Hodgkin lymphoma therapy
CN106905191B (zh) * 2017-03-05 2019-03-29 北京化工大学 一种含有羟肟酸基团的氮芥类化合物及其制备方法和用途
CN106883217B (zh) * 2017-04-01 2020-05-22 清华大学深圳研究生院 一种核苷碱基异羟肟酸衍生化合物及其制备方法与应用
GB201709405D0 (en) * 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating ovarian cancer
GB201709403D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating sarcoma
GB201709402D0 (en) 2017-06-13 2017-07-26 Euro Celtique Sa Compounds for treating t-pll
GB201709406D0 (en) 2017-06-13 2017-07-26 Euro-Cletique S A Compounds for treating TNBC
CA3071345A1 (en) * 2017-07-28 2019-01-31 Yale University Anticancer drugs and methods of making and using same
US11199529B2 (en) 2017-09-21 2021-12-14 Becton, Dickinson And Company Hazardous contaminant collection kit and rapid testing
CN108299313B (zh) * 2018-01-16 2020-10-02 长沙霍滋生物科技有限公司 一种化合物及其在药学上的应用
CN109516957A (zh) * 2018-08-03 2019-03-26 杭州梯诺医药科技有限公司 Nl-101多晶型及其制备方法
WO2020026054A1 (en) * 2018-08-03 2020-02-06 Cellix Bio Private Limited Compositions and methods for the treatment of cancer
CA3110611A1 (en) * 2018-09-01 2020-03-05 Beijing Showby Pharmaceutical Co., Ltd. Phosphate of platinum compound and preparation method therefor
AU2019402158A1 (en) * 2018-12-18 2021-06-10 Mundipharma International Corporation Limited Compounds for treating lymphoma or a T-cell malignant disease
CN212748381U (zh) 2019-01-28 2021-03-19 贝克顿·迪金森公司 一种有害污染物检测系统和一种有害污染物收集装置
CN112209884B (zh) * 2019-07-12 2022-11-11 杭州梯诺医药科技有限公司 1-h苯并咪唑衍生物、制备方法及其应用
CN113307829B (zh) * 2021-05-08 2022-05-24 苏州科技大学 一种以异羟肟酸衍生物为配体的铂(ii)配合物及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5369108A (en) 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
EP1598067B1 (en) 2000-09-29 2009-05-06 TopoTarget UK Limited Carbamic acid compounds comprising an amide linkage for the treatment of malaria
JP4993374B2 (ja) * 2004-04-05 2012-08-08 メルク エイチディーエーシー リサーチ エルエルシー ヒストン脱アセチル化酵素インヒビタープロドラッグ
WO2007134169A2 (en) 2006-05-10 2007-11-22 Nuada, Llc Indole, benzimidazole, and benzolactam boronic acid compounds, analogs thereof and methods of use thereof
US8436190B2 (en) 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
GB0621160D0 (en) * 2006-10-24 2006-12-06 Imp College Innovations Ltd Compounds and uses thereof
WO2009100045A1 (en) 2008-02-04 2009-08-13 Translational Genomics Research Institute Compounds, pharmaceutical compositions and methods of use of hydroxamic acid derivatives
CA2750413C (en) * 2009-01-23 2016-06-21 Northlake Biosciences Llc Hydroxamic acid derivatives

Also Published As

Publication number Publication date
CA2750413A1 (en) 2010-07-29
WO2010085377A3 (en) 2011-03-31
SMT201500196B (it) 2015-10-30
PL2389375T3 (pl) 2015-11-30
JP5576402B2 (ja) 2014-08-20
ME02254B (me) 2015-12-31
USRE46144E1 (en) 2016-09-13
SI2389375T1 (sl) 2015-11-30
DK2389375T3 (en) 2015-08-24
HRP20150778T1 (hr) 2015-08-28
EP2389375A4 (en) 2012-09-19
CN102186842B (zh) 2014-07-23
US9096627B2 (en) 2015-08-04
US20110269706A1 (en) 2011-11-03
CY1116602T1 (el) 2018-03-07
US8609864B2 (en) 2013-12-17
EP2389375A2 (en) 2011-11-30
CA2750413C (en) 2016-06-21
ES2544803T3 (es) 2015-09-04
CN102186842A (zh) 2011-09-14
JP2012515776A (ja) 2012-07-12
WO2010085377A2 (en) 2010-07-29
RS54192B1 (en) 2015-12-31
EP2389375B1 (en) 2015-05-20
US20140066419A1 (en) 2014-03-06
PT2389375E (pt) 2015-09-17

Similar Documents

Publication Publication Date Title
EP2389375B1 (en) Hydroxamic acid derivatives
JP7327802B2 (ja) 縮合ヘテロ－ヘテロ二環式化合物およびその使用方法
US20220009911A1 (en) Inhibitors of cxcr2
JP2023041763A (ja) 縮合ｎ－複素環式化合物およびその使用方法
EP3423443B1 (en) Cyano-substituted indole compounds and uses thereof as lsd1 inhibitors
EP3256109B1 (en) Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
JP2020521741A (ja) がんの処置のための化合物およびその使用の方法
JP2020521740A (ja) 変異体ｋｒａｓ、ｈｒａｓまたはｎｒａｓの調節因子としてのキナゾリン誘導体
CN108779097A (zh) 包含取代的杂环基的2-取代的喹唑啉化合物及其使用方法
CN103957918A (zh) 激酶抑制剂多晶型物
AU2016331955A1 (en) Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
CN108026046A (zh) 取代的喹唑啉化合物及其作为g12c突变体kras、hras和/或nras蛋白质的抑制剂的用途
JP2015516462A (ja) 単環式ヘテロアリールシクロアルキルジアミン誘導体
EP4338801A2 (en) Crystalline forms of a phosphoinositide 3-kinase (pi3k) inhibitor
CN116113406A (zh) Gas41抑制剂及其使用方法